Search Results - yi-ping+li

1 Results

Sort By:

Repurposing FDA-approved Drug Nilotinib for Cancer Cachexia Treatment

Nilotinib (TasignaTM) is an off-patent, FDA-approved kinase inhibitor. Researchers at UTHealth have discovered it as a promising repurposed drug for muscle wasting treatment at a significantly lower than FDA-approved dose. At 500 nM in vitro, it abrogates muscle catabolism without suppressing myogenesis by selectively inhibiting p38β MAPK, and...

Published: 8/15/2023 | Inventor(s): Yi-Ping Li

Keywords(s):

Category(s): Therapeutics